Search jobs 17-Dec-2020 Immune Regulation Appoints New Chairman and Builds Out Senior Management Team with Standout Industry Professionals in the US
LONDON, UK and NEW ORLEANS, US, December 17, 2020 / B3C newswire / Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its first-in-class immune resetting therapies for autoimmune and allergic diseases.
Veteran biotech executive
Peter Greenleaf has been appointed
Chairman of the Board of Directors. Peter currently serves as the CEO and member of the Board of Directors of autoimmune therapeutics company Aurinia, (NASDAQ; AUPH / TSX; AUP). Previously, Peter served as the CEO of Cerecor Inc. (Nasdaq; CERC), the CEO and Chairman of Sucampo Pharmaceuticals Inc. (NASDAQ; SCMP),